Last reviewed · How we verify
Gentian violet 0.00165% solution — Competitive Intelligence Brief
phase 3
Triphenylmethane dye antimicrobial
Infectious Disease / Dermatology
Small molecule
Live · refreshed every 30 min
Target snapshot
Gentian violet 0.00165% solution (Gentian violet 0.00165% solution) — Kamuzu University of Health Sciences. Gentian violet is a triphenylmethane dye that exerts antimicrobial and antifungal effects by intercalating into microbial DNA and disrupting cellular function.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Gentian violet 0.00165% solution TARGET | Gentian violet 0.00165% solution | Kamuzu University of Health Sciences | phase 3 | Triphenylmethane dye antimicrobial |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Triphenylmethane dye antimicrobial class)
- Kamuzu University of Health Sciences · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Gentian violet 0.00165% solution CI watch — RSS
- Gentian violet 0.00165% solution CI watch — Atom
- Gentian violet 0.00165% solution CI watch — JSON
- Gentian violet 0.00165% solution alone — RSS
- Whole Triphenylmethane dye antimicrobial class — RSS
Cite this brief
Drug Landscape (2026). Gentian violet 0.00165% solution — Competitive Intelligence Brief. https://druglandscape.com/ci/gentian-violet-0-00165-solution. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing